Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1990 1
1991 3
1993 1
1994 1
1995 1
1996 1
1998 3
1999 3
2001 1
2002 1
2003 2
2006 1
2008 3
2009 2
2010 3
2011 3
2012 1
2013 1
2014 4
2015 4
2016 9
2017 8
2018 8
2019 10
2020 16
2021 16
2022 15
2023 14

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Pérez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jiménez-Velasco A, Lakhwani S, Casado LF, Rosell A, Escola A, Fernández MJ, Garcia-Hernandez C, Cervero C, Mora E, Sagüés M, Suarez-Varela S, Vélez P, Carrascosa Mastell P, Bitaube RF, Serrano L, Cortes M, Vera Goñi JA, Steegmann JL, de Soria VGG, Alonso-Dominguez JM, Araujo MC, Coll AP, Hernandez-Boluda JC, García-Gutiérrez V. Luna A, et al. Among authors: perez encinas m. Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23. Ann Hematol. 2022. PMID: 35997804 Free PMC article.
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
Labrador J, Saiz-Rodríguez M, de Miguel D, de Laiglesia A, Rodríguez-Medina C, Vidriales MB, Pérez-Encinas M, Sánchez-Sánchez MJ, Cuello R, Roldán-Pérez A, Vives S, Benzo-Callejo G, Colorado M, García-Fortes M, Sayas MJ, Olivier C, Recio I, Conde-Royo D, Bienert-García Á, Vahi M, Muñoz-García C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas MÁ, Martínez-Cuadrón D, Sanz MÁ, Montesinos P. Labrador J, et al. Among authors: perez encinas m. Cancers (Basel). 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734. Cancers (Basel). 2022. PMID: 35406512 Free PMC article.
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G, Álvarez-Larrán A, Harrison C, Martínez-Ávila JC, Hernández-Boluda JC, Ferrer-Marín F, Radia DH, Mora E, Francis S, González-Martínez T, Goddard K, Pérez-Encinas M, Narayanan S, Raya JM, Singh V, Gutiérrez X, Toth P, Amat-Martínez P, Mcilwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares C, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufián L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martínez-López J, Ayala R, Cross NCP. Carreño-Tarragona G, et al. Among authors: perez encinas m. Blood Adv. 2023 May 9;7(9):1672-1681. doi: 10.1182/bloodadvances.2022008204. Blood Adv. 2023. PMID: 36375042 Free PMC article.
[Linagliptin-induced liver toxicity].
Bartolomé-García E, Sanz-Márquez S, Pérez-Encinas M. Bartolomé-García E, et al. Among authors: perez encinas m. Farm Hosp. 2017 Jul 1;41(4):561-562. doi: 10.7399/fh.2017.41.4.10763. Farm Hosp. 2017. PMID: 28683709 Spanish. No abstract available.
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V, Gasior M, Cuevas B, Angona A, Gómez-Casares MT, Martínez CM, Magro E, Ayala R, Del Orbe-Barreto R, Pérez-López R, Fox ML, Raya JM, Guerrero L, García-Hernández C, Caballero G, Murillo I, Xicoy B, Ramírez MJ, Carreño-Tarragona G, Hernández-Boluda JC, Pereira A; MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas). Alvarez-Larrán A, et al. Among authors: perez encinas m. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13. Cancer. 2022. PMID: 35417564 Free PMC article.
Erratum found in «Farmacia Hospitalaria. 2021;45(1):32-40».
Pérez-Encinas M, Lozano-Blázquez A, García-Pellicer J, Torre-Lloveras I, Poveda-Andrés JL, Calleja-Hernández MÁ. Pérez-Encinas M, et al. Farm Hosp. 2021 Jun 9;45(4):11740. doi: 10.7399/fh.11740. Farm Hosp. 2021. PMID: 34218770 English. No abstract available.
Familial myeloproliferative syndrome.
Pérez-Encinas M, Bello JL, Pérez-Crespo S, De Miguel R, Tome S. Pérez-Encinas M, et al. Am J Hematol. 1994 Jul;46(3):225-9. doi: 10.1002/ajh.2830460312. Am J Hematol. 1994. PMID: 8192153
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A, Bao Pérez L, Mosquera Torre A, Peleteiro Raíndo A, Cid López M, Díaz Arias JÁ, Ferreiro Ferro R, Antelo Rodríguez B, González Pérez MS, Albors Ferreiro M, Alonso Vence N, Pérez Encinas MM, Bello López JL, Martinelli G, Cerchione C. Mosquera Orgueira A, et al. Among authors: perez encinas mm. Minerva Med. 2020 Oct;111(5):427-442. doi: 10.23736/S0026-4806.20.06989-X. Epub 2020 Sep 21. Minerva Med. 2020. PMID: 32955823 Free article. Review.
[Orbital lymphomas. Presentation of nine cases].
Rey-Porca C, Pérez-Encinas M, González F. Rey-Porca C, et al. Among authors: perez encinas m. Arch Soc Esp Oftalmol. 2008 Feb;83(2):95-103. doi: 10.4321/s0365-66912008000200007. Arch Soc Esp Oftalmol. 2008. PMID: 18260020 Review. Spanish.
119 results